Putative Clinical Potential of ERBB2 Amplification Assessment by ddPCR in FFPE-DNA and cfDNA of Gastroesophageal Adenocarcinoma Patients
Open Access
- 27 April 2022
- Vol. 14 (9), 2180
- https://doi.org/10.3390/cancers14092180
Abstract
Anti-HER2 monoclonal antibody trastuzumab improves the survival of those patients with advanced gastroesophageal adenocarcinoma (GEA) exhibiting HER2/ERBB2 overexpression/amplification. The current gold standard methods used to diagnose the HER2 status in GEA are immunohistochemistry (IHC) and silver or fluorescence in situ hybridization (SISH or FISH). However, they do not permit spatial and temporal tumor monitoring, nor do they overcome intra-cancer heterogeneity. Droplet digital PCR (ddPCR) was used to implement the assessment of HER2 status in formalin-fixed paraffin-embedded (FFPE) tumor DNA from a retrospective cohort (86 patients) and in cell-free DNA (cfDNA) samples from a prospective cohort (28 patients). In comparison to IHC/SISH, ddPCR assay revealed ERBB2 amplification in a larger patient fraction, including HER2 2+ and 0–1+ of the retrospective cohort (45.3% vs. 15.1%). In addition, a considerable number of HER2 2+ and 0–1+ prospective patients who were negative in FFPE by both IHC/SISH and ddPCR, showed ERBB2 amplification in the cfDNA collected just before surgery. cfDNA analysis in a few longitudinal cases revealed an increasing ERBB2 trend at progression. In conclusion, ddPCR in liquid biopsy may improve the detection rate of HER2 positive patients, preventing those patients who could benefit from targeted therapy from being incorrectly excluded.Funding Information
- Italian Ministry of Health (RICERCA CORRENTE 2019-2020)
This publication has 48 references indexed in Scilit:
- Droplet digital PCR measurement of HER2 in patients with gastric cancerBritish Journal of Cancer, 2015
- Monitoring gastric cancer progression with circulating tumour DNABritish Journal of Cancer, 2014
- Comprehensive molecular characterization of gastric adenocarcinomaNature, 2014
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III StudyJournal of Clinical Oncology, 2014
- The Digital MIQE Guidelines: Minimum Information for Publication of Quantitative Digital PCR ExperimentsClinical Chemistry, 2013
- Are Biopsy Specimens Predictive of HER2 Status in Gastric Cancer Patients?Digestive Diseases and Sciences, 2012
- HER2 Testing in Gastric CancerAdvances in Anatomic Pathology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic targetAnnals of Oncology, 2008
- Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumabAnnals of Oncology, 2005